

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE TO  
(Rule 14d-100)  
Tender Offer Statement Under Section 14(d)(1)  
or Section 13(e)(1) of the Securities Exchange Act of 1934  
(Amendment No. 3)

and

SCHEDULE 13D  
(Rule 13d-101)

(Amendment No. 1)

VYSIS, INC.  
(Name of Subject Company (Issuer))

RAINBOW ACQUISITION CORP.  
a wholly owned subsidiary of  
ABBOTT LABORATORIES  
(Names of Filing Persons (Offerors))

COMMON STOCK, PAR VALUE \$.001 PER SHARE  
(Title of Class of Securities)

928961-10-1  
(CUSIP Number of Class of Securities)

Jose M. de Lasa  
Senior Vice President, Secretary and General Counsel  
Abbott Laboratories  
100 Abbott Park Road  
Abbott Park, Illinois 60064-6400  
(847) 937-6100  
(Name, address and telephone number of  
person authorized to receive notices  
and communications on behalf of filing persons)

With a copy to:  
Charles W. Mulaney, Jr., Esq.  
Skadden, Arps, Slate, Meagher & Flom (Illinois)  
333 West Wacker Drive  
Chicago, Illinois 60606  
Telephone: (312) 407-0700  
CALCULATION OF FILING FEE

Transaction Valuation*	Amount of Filing Fee
\$375,598,258.50	\$75,119.66

\* Estimated for purposes of calculating the filing fee only. The filing fee calculation assumes the purchase of 10,291,789 outstanding shares of common stock of Vysis, Inc. at a purchase price of \$30.50 per share. The transaction value also includes the offer price of \$30.50 per share, multiplied by 2,002,908, the estimated number of options outstanding under Vysis, Inc's employee stock option plans which are or will be, as a result of the transaction, exercisable for shares of common stock of Vysis, Inc. The amount of the filing fee calculated in accordance with Rule 0-11 of the Securities Exchange Act of 1934, as amended, equals 1/50 of 1% of the transaction value.

[X] Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number or the Form or Schedule and the date of its filing.

Amount Previously Paid: \$75,119.66 Filing party: Abbott Laboratories and Rainbow Acquisition Corp.  
Form or Registration No.: Schedule TO Date Filed: October 31, 2001

[ ] Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer. Check the appropriate boxes below to designate any transactions to which the statement relates:

[X] third-party tender offer subject to Rule 14d-1. [ ] issuer tender offer subject to Rule 13e-4.  
[ ] going-private transaction subject to Rule 13e-3.

[X] amendment to Schedule 13D under Rule 13d-2.  
Check the following box if the filing is a final amendment  
reporting the results of the tender offer: [X]

=====  
-----  
CUSIP No. 928961-10-1  
-----

-----  
1 NAME OF REPORTING PERSON  
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)  
ABBOTT LABORATORIES (I.R.S. IDENTIFICATION NO. 36-0698440)  
-----

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)   
(b)

3 SEC USE ONLY  
-----

4 SOURCE OF FUNDS  
00  
-----

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)

6 CITIZENSHIP OR PLACE OF ORGANIZATION  
ILLINOIS  
-----

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

7	SOLE VOTING POWER	-0-
8	SHARED VOTING POWER	10,192,813
9	SOLE DISPOSITIVE POWER	-0-
10	SHARED DISPOSITIVE POWER	10,192,813

-----

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
10,192,813  
-----

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES EXCLUDES CERTAIN ISSUES

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
98.6%  
-----

14 TYPE OF REPORTING PERSON  
CO  
-----

-----  
CUSIP No. 928961-10-1  
-----

xxx

-----  
1 NAME OF REPORTING PERSON  
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)  
RAINBOW ACQUISITION CORP.  
-----

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)   
(b)

3 SEC USE ONLY  
-----

4 SOURCE OF FUNDS  
00  
-----

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)

## 6 CITIZENSHIP OR PLACE OF ORGANIZATION

DELAWARE

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7	SOLE VOTING POWER -0-
	8	SHARED VOTING POWER 10,192,813
	9	SOLE DISPOSITIVE POWER -0-
	10	SHARED DISPOSITIVE POWER 10,192,813
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  10,192,813	
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES EXCLUDES CERTAIN ISSUES <input type="checkbox"/>	
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  98.6%	
14	TYPE OF REPORTING PERSON CO	

This Amendment No. 3 (the "Amendment") amends and supplements the Tender Offer Statement on Schedule T0 filed with the Securities and Exchange Commission (the "Commission") on October 31, 2001, as amended (the "Schedule T0") by Rainbow Acquisition Corp., a Delaware corporation (the "Purchaser") and a wholly owned subsidiary of Abbott Laboratories, an Illinois corporation ("Abbott") and the Schedule 13D filed with the Commission by Purchaser and Abbott on November 1, 2001. The Schedule T0 relates to the offer by the Purchaser to purchase all outstanding shares of common stock, par value \$.001 per share (the "Shares"), of Vysis, Inc., a Delaware corporation (the "Company"), at \$30.50 per Share net to the seller in cash, upon the terms and conditions set forth in its Offer to Purchase dated October 31, 2001 (the "Offer to Purchase") and in the related Letter of Transmittal (which, together with the Offer to Purchase and any amendments or supplements thereto, collectively constitute the "Offer"). Capitalized terms used and not otherwise defined herein shall have the meanings assigned to such terms in the Offer to Purchase or in the Schedule T0.

Items 4, 8 and 11.

Items 4, 8 and 11 are hereby amended and supplemented to include the following:

The Offer expired at 12:00 midnight, New York City time, on November 29, 2001, and was not extended. Based on information provided by EquiServe Trust Company, N.A., the depository for the Offer (the "Depository"), 10,192,813 Shares (including 346,500 Shares subject to guarantee of delivery), representing approximately 98.6% of the outstanding Shares, were validly tendered pursuant to the Offer. Purchaser has accepted for payment all Shares validly tendered and not withdrawn prior to the expiration of the Offer.

Pursuant to the terms of the Agreement and Plan of Merger, dated as of October 24, 2001, among Abbott, Purchaser and the Company, Abbott intends to cause the merger of Purchaser with and into the Company (the "Merger") following the expiration of the Offer. Upon consummation of the Merger, each Share issued and outstanding immediately prior to the effective time of the Merger (other than Shares owned by Abbott or any of its subsidiaries or held by the Company as treasury stock or owned by any subsidiaries of the Company, all of which will be cancelled and retired and will cease to exist, and other than Shares that are held by stockholders, if any, who properly exercise their dissenters' rights in accordance with Delaware law) will be cancelled and converted automatically into the right to receive \$30.50, without interest thereon, payable to the holder of such Share.

On November 30, 2001, Abbott issued a press release announcing the results of the Offer. The full text of press release is filed as Exhibit (a)(5)(E) and is incorporated by reference herein.

Item 11. Additional Information.

Sections (a)(2) and (a)(3) of Item 11 are hereby amended and supplemented to include the following:

On November 29, 2001, the German Federal Cartel Office approved the proposed acquisition of the Company by Abbott.

Item 12. Exhibits.

- (a)(1)(A)\* Offer to Purchase dated October 31, 2001.
- (a)(1)(B)\* Letter of Transmittal.
- (a)(1)(C)\* Notice of Guaranteed Delivery.
- (a)(1)(D)\* Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.
- (a)(1)(E)\* Letter to Clients for use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.
- (a)(1)(F)\* Guidelines for Certification of Taxpayer Identification Number (TIN) on Substitute Form W-9.
- (a)(5)(A)\* Press Release issued by Abbott on October 24, 2001, incorporated herein by reference to the Schedule TO filed by Abbott on October 24, 2001.
- (a)(5)(B)\* Summary Advertisement as published in The Wall Street Journal on October 31, 2001.
- (a)(5)(C)\* Press Release issued by Abbott on October 31, 2001.
- (a)(5)(D)\* Press Release issued by Abbott on November 23, 2001.
- (a)(5)(E) Press Release issued by Abbott on November 30, 2001.
- (b) Not applicable.
- (d)(1)\* Agreement and Plan of Merger, dated as of October 24, 2001, by and among Abbott, the Purchaser, and Vysis.
- (d)(2)\* Stockholder Agreement, dated as of October 24, 2001, by and among Abbott, the Purchaser, Amoco Technology Company and BP America Inc.
- (d)(3)\* Confidentiality Agreement, dated April 17, 2001, as amended on August 21, 2001, between Vysis and Abbott.
- (d)(4)\* Confidentiality Agreement, dated August 21, 2001, between BP Corporation North America Inc. and Abbott.
- (g) Not applicable.
- (h) Not applicable.

- - - - -  
\* Previously filed.

SIGNATURE

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

ABBOTT LABORATORIES

By: /s/ RICHARD A. GONZALEZ  
-----  
Name: Richard A. Gonzalez  
Title: Executive Vice President,  
Medical Products

RAINBOW ACQUISITION CORP.

By: /s/ THOMAS C. FREYMAN  
-----  
Name: Thomas C. Freyman  
Title: Vice President

EXHIBIT INDEX

Exhibit No. -----	Exhibit Name -----
(a)(1)(A)*	Offer to Purchase dated October 31, 2001.
(a)(1)(B)*	Letter of Transmittal.
(a)(1)(C)*	Notice of Guaranteed Delivery.
(a)(1)(D)*	Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.
(a)(1)(E)*	Letter to Clients for use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.
(a)(1)(F)*	Guidelines for Certification of Taxpayer Identification Number (TIN) on Substitute Form W-9.
(a)(5)(A)*	Press Release issued by Abbott on October 24, 2001, incorporated herein by reference to the Schedule TO filed by Abbott on October 24, 2001.
(a)(5)(B)*	Summary Advertisement as published in The Wall Street Journal on October 31, 2001.
(a)(5)(C)*	Press Release issued by Abbott on October 31, 2001.
(a)(5)(D)*	Press Release issued by Abbott on November 23, 2001.
(a)(5)(E)	Press Release issued by Abbott on November 30, 2001.
(b)	Not applicable.
(d)(1)*	Agreement and Plan of Merger, dated as of October 24, 2001, by and among Abbott, the Purchaser and Vysis.
(d)(2)*	Stockholder Agreement, dated as of October 24, 2001, by and among Abbott, the Purchaser, Amoco Technology Company and BP America Inc.
(d)(3)*	Confidentiality Agreement, dated April 17, 2001, as amended on August 21, 2001, between Vysis and Abbott.
(d)(4)*	Confidentiality Agreement, dated August 21, 2001, between BP Corporation North America Inc. and Abbott.
(g)	Not applicable.
(h)	Not applicable.

-----  
\* Previously filed.

For Immediate Release

Media:  
Kathleen O'Neil  
(847) 938-3895

Financial Community:  
John Thomas  
(847) 938-2655

ABBOTT LABORATORIES ACQUIRES CONTROL OF VYSIS, INC.

ABBOTT PARK, Ill., November 30, 2001-- Abbott Laboratories (NYSE: ABT) announced today that it has acquired control of Vysis, Inc. (Nasdaq: VYSI). Abbott's cash tender offer to purchase all of the outstanding common stock of Vysis expired, as scheduled, at midnight, New York City time, on Thursday, November 29, 2001. The offer has not been extended.

A total of 10,192,813 shares of Vysis common stock were validly tendered and not withdrawn prior to the expiration of the offer, including 346,500 shares subject to guaranteed delivery procedures. Abbott has accepted all of these shares for payment. These shares represent approximately 98.6 percent of Vysis's outstanding shares.

As the final step of the acquisition process, Abbott intends to consummate a merger in which remaining Vysis shareholders will receive the same \$30.50 cash price per share as paid in the tender offer.

Abbott Laboratories is a global, diversified health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals, nutritionals, and medical products, including devices and diagnostics. The company employs approximately 70,000 people and markets its products in more than 130 countries. In 2000, the company's sales and net earnings were \$13.7 billion and \$2.8 billion, respectively, with diluted earnings per share of \$1.78.

Abbott's news releases and other information are available on the company's Web site at [www.abbott.com](http://www.abbott.com).

Vysis is a genomic disease management company that develops, commercializes and markets DNA-based clinical products providing information critical to the evaluation and management of cancer, prenatal disorders and other genetic diseases. The company has direct sales operations in the United States and Europe; a marketing partnership in Japan with Fujisawa Pharmaceutical Co.; and a worldwide distribution network. Vysis' news releases and other information are available on the company's Web site at [www.vysis.com](http://www.vysis.com).